The legal imperative for treating rare disorders
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 1-135
Abstract
Life-saving orphan drugs are some of the most expensive medicines. European Union governments aim to accommodate their provision within stretched healthcare budgets but face pressure to reduce funding of such treatments. Patients struggle to retain or gain access to them as their special status is questioned, causing distress and in some cases, fears of premature death. In the UK and EU reimbursement and pricing model of drugs, and orphan drugs in particular, is being re-evaluated.Keywords
This publication has 17 references indexed in Scilit:
- The Convention on the Rights of Persons With Disabilities: A Foundation for Ethical Disability and Health Research in Developing CountriesAmerican Journal of Public Health, 2014
- THE SAFER CLINICAL SYSTEMS PROJECT IN RENAL CAREJournal of Renal Care, 2013
- ADA Perceived Disability Claims: A Decision-Tree AnalysisJournal of Occupational Rehabilitation, 2013
- Primary posterior perineal herniation of urinary bladderJournal of Minimal Access Surgery, 2013
- Is it time to revisit orphan drug policies?BMJ, 2010
- Lessons from the Experience of U.N. Convention on the Rights of Persons with Disabilities: Addressing the Democratic Deficit in Global Health GovernanceJournal of Law, Medicine & Ethics, 2010
- Co-payments in the NHS: an analysis of the normative argumentsHealth Economics, Policy and Law, 2010
- Why is the press so nasty to NICE?BMJ, 2008
- LOSING THE WOOD FOR THE TREES: BURKE AND THE COURT OF APPEALMedical Law Review, 2006
- Ethical issues in funding orphan drug research and developmentJournal of Medical Ethics, 2005